ALK gains Torii as Japanese partner for selected immunotherapies
This article was originally published in Scrip
Japan Tobacco's pharma marketing arm Torii Pharmaceutical will pay €30 million upfront for exclusive Japanese development, commercialisation and distribution rights to immunotherapy products for house dust mite-related asthma and allergic rhinitis developed by ALK-Abell�.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.